[A25-163] Guselkumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2026
Project no.:
A25-163
Commission:
Commission awarded on 23.12.2025 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Children and adolescents from the age of 6 years with moderate to severe plaque psoriasis for whom systemic therapy is an option
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
https://doi.org/10.60584/A25-163
| Project no. | Title | Status |
|---|---|---|
| A25-75 | Guselkumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-74 | Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-112 | Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-60 | Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |